Wells Fargo’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-40,688
| Closed | -$61K | – | 7765 |
|
|
2023
Q1 | $61K | Buy |
40,688
+14,004
| +52% | +$18.9K | ﹤0.01% | 5060 |
|
|
2022
Q4 | $26.7K | Buy |
26,684
+16,471
| +161% | +$22.2K | ﹤0.01% | 5136 |
|
|
2022
Q3 | $18K | Buy |
10,213
+3,348
| +49% | +$9.71K | ﹤0.01% | 5468 |
|
|
2022
Q2 | $20K | Sell |
6,865
-4,737
| -41% | -$11.7K | ﹤0.01% | 5466 |
|
|
2022
Q1 | $32K | Sell |
11,602
-10,689
| -48% | -$33.6K | ﹤0.01% | 5851 |
|
|
2021
Q4 | $104K | Buy |
22,291
+74
| +0.3% | +$463 | ﹤0.01% | 5612 |
|
|
2021
Q3 | $189K | Sell |
22,217
-43,428
| -66% | -$614K | ﹤0.01% | 5120 |
|
|
2021
Q2 | $1.08M | Buy |
65,645
+4,524
| +7% | +$91.4K | ﹤0.01% | 4163 |
|
|
2021
Q1 | $1.35M | Buy |
61,121
+25,668
| +72% | +$700K | ﹤0.01% | 4028 |
|
|
2020
Q4 | $1.1M | Buy |
35,453
+1,901
| +6% | +$48.1K | ﹤0.01% | 3960 |
|
|
2020
Q3 | $682K | Sell |
33,552
-17,479
| -34% | -$307K | ﹤0.01% | 4132 |
|
|
2020
Q2 | $783K | Buy |
51,031
+29,879
| +141% | +$345K | ﹤0.01% | 4007 |
|
|
2020
Q1 | $163K | Buy |
21,152
+1,726
| +9% | +$21.1K | ﹤0.01% | 4806 |
|
|
2019
Q4 | $278K | Buy |
19,426
+10,960
| +129% | +$169K | ﹤0.01% | 4772 |
|
|
2019
Q3 | $127K | Buy |
8,466
+8,452
| +60,371% | +$132K | ﹤0.01% | 5211 |
|
|
2019
Q2 | $0 | Buy |
+14
| New | +$223 | ﹤0.01% | 6711 |
|
Wells Fargo's TCRR Position: Q2 2023 in Review
Wells Fargo sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q2 2023, closing a stake of 40,688 shares — an estimated $61K sold.
Wells Fargo first reported a position in TCRR in Q2 2019 and held it in 16 quarters. The position peaked at $1.35M in Q1 2021. 0 funds tracked by Wall St. Rank hold TCRR as of Q2 2023.
- Wells Fargo reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- Wells Fargo sold 40,688 TCR2 Therapeutics Inc. Common Stock shares in Q2 2023, an estimated $61K.
- Wells Fargo first reported a position in TCR2 Therapeutics Inc. Common Stock in Q2 2019 and held it in 16 quarters.
- Wells Fargo's TCR2 Therapeutics Inc. Common Stock position peaked at $1.35M in Q1 2021.
- 0 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q2 2023.
Based on Wells Fargo's 13F filing for Q2 2023, filed 15 Aug 2023.